Drug details
Udenyca (pegfilgrastim-cbqv injection)
type of Hematopoietic Growth Factors
Udenyca (pegfilgrastim-cbqv) is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
This drug may have the following side effects:
- hives,
- difficulty breathing,
- swelling of your face, lips, tongue, or throat,
- fever,
- skin rash,
- easy bruising,
- unusual bleeding,
- lightheadedness,
- shortness of breath,
- rapid breathing,
- tiredness,
- stomach pain,
- dizziness,
- back pain,
- wheezing,
- sweating,
- little or no urination,
- decreased urination,
- purple or red spots under your skin,
- bruising,
- sudden swelling,
- feeling of fullness,
- pain while breathing,
- sudden or severe pain in your left upper stomach spreading up to your shoulder,
- warmth or tingly feeling,
- puffiness,
- pink or dark urine, and
- swelling in your face or lower legs
- hard lump where the medicine was injected,
The following drugs are related to Udenyca, either as a replacement or used together:
- Afinitor (everolimus tablets)
- Afinitor Disperz (everolimus tablets)
- Aldara (imiquimod)
- Aliqopa (copanlisib for injection, for intravenous use)
- Alunbrig (brigatinib tablets)
- Carac (fluorouracil)
- Erbitux (cetuximab)
- Empliciti (elotuzumab for injection)
- Erivedge (vismodegib)
- Gleevec (imatinib mesylate)
- Jelmyto (mitomycin for pyelocalyceal solution)
- Neulasta (pegfilgrastim)
- Nyvepria (pegfilgrastim-apgf injection)
- Ziextenzo (pegfilgrastim-bmez injection)
- Stimufend (pegfilgrastim-fpgk)